In a recent meta-analysis, Zhang and colleagues confirmed the efficacy of antiPD-1/PD-L1 antibodies for various cancers, especially melanoma, non-small-cell lung cancer (NSCLC) and renal cell carcinoma (RCC) [20]. The gene discussed is CD274; the disease is melanoma.